Spots Global Cancer Trial Database for Case Series Study of Biliary Tract Cancer Patients in Japan

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Case Series Study of Biliary Tract Cancer Patients in Japan

Official Title: Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer

Study ID: NCT01294085

Conditions

Biliary Tract Cancer

Interventions

Study Description

Brief Summary: To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.

Detailed Description: Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.